With 0.96 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.95 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $2.27 whereas the lowest price it dropped to was $2.225. The 52-week range on CRON shows that it touched its highest point at $3.14 and its lowest point at $1.70 during that stretch. It currently has a 1-year price target of $2.67. Beta for the stock currently stands at 0.97.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRON was up-trending over the past week, with a rise of 3.23%, but this was up by 3.23% over a month. Three-month performance dropped to -0.44% while six-month performance fell -16.42%. The stock gained 12.00% in the past year, while it has gained 7.18% so far this year. A look at the trailing 12-month EPS for CRON yields -0.15 with Next year EPS estimates of 0.01. For the next quarter, that number is 0.01. This implies an EPS growth rate of 53.70% for this year and 112.00% for next year. EPS is expected to grow by 45.80% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -9.06%.
Float and Shares Shorts:
At present, 381.30 million CRON shares are outstanding with a float of 200.30 million shares on hand for trading. On 2024-09-13, short shares totaled 5.1 million, which was 133.00001 higher than short shares on 1723680000. In addition to Mr. Michael Ryan Gorenstein J.D. as the firm’s President, CEO & Chairman, Mr. James Holm serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.15981 of CRON’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, CRON reported revenue of $27762000.0 and operating income of -$15014000.0. The EBITDA in the recently reported quarter was -$2966000.0 and diluted EPS was -$0.02.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRON since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
Dividends & Yield:
In terms of dividends, CRON has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and CRON currently yields $0.00. In the past year, CRON’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, CRON has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.
